Gilead Keeps Close Eye On Stormy Remdesivir Situation In India

Gilead is closely evaluating the situation for remdesivir in India as the country tackles shortages of the drug, which has several local licensees, with instances of black marketing adding to the local woes. The US firm clearly will not want any momentum towards possible compulsory licensing as initiated by Hungary and Russia, even as Indian firms have cut prices of the antiviral.